How to navigate loss of exclusivity with a strategic commercial playbook

June 17, 2026

A framework for maximizing value before, during, and after loss of exclusivity

Loss of Exclusivity (LOE) remains one of the most significant commercial inflection points in the pharmaceutical product lifecycle. As numerous high-value biologics and specialty products approach patent expiration, manufacturers face increasing pressure to protect revenue, maintain patient access, and optimize portfolio performance in an increasingly competitive environment.

While LOE is often viewed as the end of a product’s commercial journey, it can also serve as a strategic opportunity to maximize remaining asset value, redeploy resources effectively, and strengthen broader portfolio objectives. A well-defined, proactive commercial strategy is essential to mitigating risks and capitalizing on potential opportunities.

Acumetis’ Playbook for Navigating Loss of Exclusivity Through Commercial Levers provides pharmaceutical leaders with a comprehensive framework to address LOE strategically.

Inside this playbook:

  • Determining the optimal timing for LOE planning based on product characteristics, competitive dynamics, and therapeutic area considerations
  • Identifying commercial strategies to mitigate revenue erosion while maintaining patient and provider engagement
  • Evaluating key commercial levers to maximize late-lifecycle asset value
  • Aligning cross-functional stakeholders around a coordinated LOE strategy and execution plan
  • Integrating LOE planning into broader portfolio, lifecycle management, and resource allocation decisions

Without a proactive approach, LOE can result in accelerated revenue decline, operational inefficiencies, fragmented decision-making, and missed opportunities to extend value. Effective planning requires organizations to anticipate market shifts, assess strategic tradeoffs, and execute with discipline well before exclusivity is lost.

Successful LOE management does not begin at the point of patent expiration. It begins years earlier through deliberate planning, cross-functional alignment, and informed decision-making.

Download the playbook to explore how leading organizations are approaching loss of exclusivity and learn practical strategies to protect value, optimize investments, and navigate transition with confidence.

 

Download the Launch Playbook Now

"*" indicates required fields

Meet the Experts:

Santosh Naik
Santosh Naik
Partner, Launch Excellence Practice Lead

Santosh Naik is a Partner at Acumetis and has 15+ years of experience working in both strategy consulting and product development.  In his current role, he leads Acumetis Launch Excellence practice and is a member of the Executive Leadership team. Santosh’s primary expertise includes advising clients on go-to-market strategy development and launch excellence and execution. In his time at Acumetis, Santosh has advised clients on over 50+ product launches and he has built brand strategies for both launch and in-line brands.

Everett Lozzi
Everett Lozzi
Principal

Everett brings extensive experience addressing complex commercialization challenges and optimizing product performance across a wide range of therapeutic areas, including neurology, psychiatry, ophthalmology, nephrology, dermatology, oncology, and rare disease. Everett takes a collaborative approach, applying insightful analysis and compelling storytelling to support teams in defining their strategic goals and developing achievable solutions.

Ali Soroush
Ali Soroush
Manager, Global Innovation

Ali has deep expertise in corporate and product strategy, launch planning, and commercial analytics. He partners with executive and senior leadership teams to instill an enterprise mindset and strengthen launch and commercialization capabilities. Ali has led successful launches across oncology, immunology, dermatology, CNS, and rare diseases, leveraging advanced analytics to uncover HCP and patient insights that drive performance. He has also developed CRMs and executive dashboards for leading pharma clients to enable data-driven decision-making.

FAQs on Launch of Exclusivity

1. What is a loss of exclusivity strategy?

A loss of exclusivity strategy is a structured approach that helps pharmaceutical companies prepare for patent expiration and increased competition. It typically includes lifecycle management, commercial optimization, stakeholder engagement, and portfolio planning to maximize asset value before and after exclusivity loss.

2. How can pharmaceutical companies reduce revenue erosion following loss of exclusivity?

Organizations can mitigate revenue erosion through proactive planning, targeted commercial initiatives, market access optimization, strategic resource allocation, and portfolio management decisions that extend product value and maintain stakeholder engagement.

3. Why is early planning important for loss of exclusivity?

The most effective LOE strategies begin years before exclusivity expires. Early planning enables organizations to evaluate competitive threats, align cross-functional teams, optimize investments, and develop a coordinated approach to managing the transition.

4. What commercial levers should be evaluated before loss of exclusivity?

Organizations should assess a range of commercial levers, including pricing and contracting strategies, market access initiatives, customer engagement approaches, lifecycle management opportunities, portfolio prioritization, and resource allocation decisions. Evaluating these factors early can help maximize asset value and support a smoother transition following loss of exclusivity.